General Dermatology

In case you missed it, this week we had news on delgocitinib sNDA for pediatric CHE, new 12-month data for clascoterone 5% in androgenetic alopecia, the rise of GLP-1 usage in dermatology, and more.

Kathleen Moe, MD, offers guidance on creating 5-star dermatology patient experience systems for faster access, consistent scripts, and guided checkout that reduce callbacks and build trust.

Dysregulation of the innate immune system, inflammatory cytokines, and abnormal blood vessel growth plays a key role in persistent redness and flushing.

Henry W. Lim, MD, FAAD's legacy highlights the impact of mentorship, research, and global advocacy in advancing inclusive dermatologic care and improving skin health worldwide.

A new case-control study found that patients with pemphigus vulgaris and bullous pemphigoid face more than twice the odds of comorbid acute stress disorder compared with matched controls.

Many participants in the mobile screening program have never previously seen a dermatologist.

In this episode, Daniel Walker, MD, FAAD, explains how GLP-1 drugs may be effective for psoriasis and HS, linking skin inflammation with weight and heart health.

Although dermatologists are not expected to routinely prescribe GLP-1 drugs, they are increasingly encountering cutaneous effects, especially hair loss and facial volume loss.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

GLP-1 agonists may aid psoriasis, wound healing, and cardiometabolic health—Daniel Walker, MD, FAAD, explains why dermatologists should start to pay attention.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

David Oberlin, MD, shares tips for integrating AAD insights and lessons into the clinic to improve patient care.

GLP-1 therapy may calm psoriasis and hidradenitis suppurativa beyond weight loss, and holistic metabolic care can address aesthetic concerns, according to Walker.

Dermatologists are exploring GLP-1 drugs for psoriasis and HS, but evidence is early—weight-loss benefits may help as add-ons, not replacements.

Around 80% of clinical trials face enrollment delays, and for rare genodermatoses with small patient pools, AI-generated synthetic control arms may offer a practical path to adequately powered studies.

In case you missed it, this week we had news on phase 3 AD SHORE trials for amlitelimab, the expansion of coverage for tirbanibulin, the start of a phase 2b/3 of brepocitinib for LPP, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Patricia M. Delgado, DNP, AGPCNP, DCNP, PMHNP, and Mohammad Jafferany, MD, discuss how integrating mental health and dermatologic care can improve outcomes for patients with chronic skin conditions.

AAD honors Henry W. Lim, MD, FAAD, with the Academy's highest honor for his work in photodermatology advances, skin of color care, and global leadership.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

Dermatology Times is looking back on the top stories in dermatology from the month of March.